GSK has announced the opening of its new global vaccines research and development center in Rockville, Maryland.
The opening of the new center is GSK’s way of strengthening and expanding its vaccine presence in the U.S.
The center in Rockville will create approximately 200 new jobs. It will cost more than $50 million over the next two years to fully develop.
“We are delighted to be opening our new facility in Rockville, GSK’s first fully dedicated vaccines R&D center located in the U.S.,” GSK Vaccines President Luc Debruyne said. “Our investment here signifies our commitment to discovering and developing new vaccines across a range of pressing public health priorities, including those important here in the U.S. It places GSK at the heart of a dynamic and cutting-edge bioscience hub in Washington, D.C. We look forward to fruitful partnerships and collaborations in this community to advance the science of vaccines and help improve health of millions of people around the world.”
The opening ceremony will include Debruyne, GSK CEO Andrew Witty and Maryland Lieutenant Gov. Boyd Rutherford. In attendance will be state and local officials, senior representatives from health institutions and GSK employees.
